Waldenstrom macroglobulinemia (WM) is a slow-growing type of non-Hodgkin lymphoma (NHL). The cancer cells make large amounts of an abnormal protein (a macroglobulin called IgM) in the blood.
WM is most often caused by mutations in the MYD88 genes; about 30-40% of patients also have a mutation in the CXCR4 gene.
X4 Pharmaceuticals is conducting a Phase 1b clinical trial, as part of a collaboration with The Leukemia & Lymphoma Society, to evaluate the study drug, mavorixafor, in combination with the marketed drug ibrutinib in patients with both MYD88 and CXCR4 mutations.
Sharon shares her experience with WM and her hope for the future.
David shares his experience with WM and his hope for the future.
Learn More:
ClinicalTrials.gov –listing for the X4 study (NCT Identifier: 04274738) contains study sites and contact information
X4 Pharmaceuticals does not review or control the content on the website to which this hyperlink connects and this hyperlink does not constitute an endorsement by X4 Pharmaceuticals of the content of any non-X4 Pharmaceuticals website.
